Recursion Pharmaceuticals announced it priced an underwritten offering of 61.54 million Class A shares at $3.25 each, aiming to raise approximately $200 million before expenses. The funds will support its AI-enabled drug discovery platform and clinical development pipeline across oncology, rare diseases, and other areas. The offering, expected to close around October 16, 2026, attracted major healthcare and institutional investors. This capital raise strengthens Recursion's position to advance its innovative medicines and technology platform.
Recursion Pharmaceuticals holds a market cap of $2.02 billion and an enterprise value of $1.54 billion as of October 15, 2026, 19:31 WIB. Despite the recent $200 million stock offering news, the stock price on Pluang is $3.41, down 8.82% in the last day, with a high trading volume of 18,610,436 shares. Pluang investors show a selling bias with 73% of order activity as Sell and 27% as Buy, reflecting cautious sentiment around the stock currently.
Recursion Pharmaceuticals announced that Sanofi has chosen their first development candidate from a joint immunology drug discovery collaboration, triggering a $10 million milestone payment to Recursion. This oral small molecule targets two inflammat...
Recursion Pharmaceuticals announced a $200 million oversubscribed follow-on stock offering backed by major healthcare investors. The company reported promising Phase 1b/2 data for REC-4881 showing significant and durable reductions in precancerous po...
